Therini Bio is at the forefront of developing innovative immunotherapies aimed at addressing neuroinflammation associated with vascular dysfunction, which is a significant contributor to severe neurological and retinal diseases. The company’s approach focuses on the toxic accumulation of fibrin deposits outside blood vessels, which triggers chronic inflammation and neuronal damage. This mechanism is particularly relevant in conditions such as Alzheimer’s Disease and Diabetic Macular Edema. Therini Bio's lead candidate, THN391, is a monoclonal antibody designed to selectively target the inflammatory epitopes on these fibrin deposits, thereby preventing the activation of immune cells like microglia and macrophages that contribute to neuroinflammation.

The scientific foundation of Therini Bio's technology is rooted in the expertise of Dr. Katerina Akassoglou, a prominent figure in neurovascular and brain immunology. The company aims to create first-in-class therapies that can effectively mitigate the harmful effects of neuroinflammation without disrupting normal coagulation processes or innate immune responses. By focusing on the underlying mechanisms of vascular dysfunction and its role in neurodegeneration, Therini Bio is positioned to make significant advancements in the treatment of debilitating diseases that currently lack effective therapies.

United States

Therini Bio, Inc. is a biotechnology company dedicated to the research and development of novel therapeutics for the treatment of neuroinflammatory diseases due to vascular dysfunction. Our approach will be generally applicable across a range of inflammatory diseases including peripheral indications. The current therapeutic target is based on novel findings by the Akassoglou lab at Gladstone/UCSF that implicate fibrin as a key driver of neuroinflammation.

Therini Bio

Company Details